Patent ID: 9161952
Filing Date: 2015-10-20
Classification: A61K,A61L,A61M

Abstract:
1. A method of treating a cardiovascular disorder in a subject in need thereof, comprising: administering to said subject a mesothelial composition comprising acellular bioremodelable mesothelial tissue, said mesothelial tissue comprising endogenous proteoglycans, transforming growth factor-β (TGF-β) and vascular endothelial growth factor (VEGF), said mesothelial tissue further comprising an exogenously added anti-arrhythmic agent selected from the group consisting of quinidine, procainamide, disopyramide, lidocaine, phenytoin, mexiletine, flecainide, propafenone, moricizine, propranolol, esmolol, timolol, metoprolol, atenolol, amiodarone, sotalol, ibutilide, dofetilide, verapamil, diltiazem, adenosine and digoxin; providing a ventricular assist device; and simultaneously providing ventricular assistance to said subject by administering said ventricular assist device and said mesothelial composition to damaged cardiovascular tissue associated with said cardiovascular disorder.